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Introduction
Despite its simple structure, the bioactive lysophospholipid mediator lysophosphatidic acid (1-or 2-acyl-lysophosphatidic acid; LPA) exerts various biological actions, including, but not limited to, platelet aggregation, smooth muscle contraction, and cell survival and proliferation. 1 In addition, LPA has also been shown to be involved in the increase in cellular motility and tumour cell invasiveness. 2, 3 These LPA actions are mediated through activation of its G-protein-coupled receptors (LPA1--4) 4, 5 or the newly identi¢ed G-protein-coupled receptor GPR92/LPA5. 6 LPA, via binding to these speci¢c G-protein-coupled receptors, activates multiple signalling pathways, including those initiated by the small GTPases Ras, Rho and Rac. 7, 8 LPA stimulates Ras via G i and subsequently activates the downstream mitogen-activated protein kinase cascade, while it mediates actomyosin-based cytoskeletal contraction through G a12/13 and the resultant Rho activation. LPA also activates Rac to promote tumour cell migration.
It is now believed that LPA, through stimulation of cell proliferation, migration and survival, contributes to cancer initiation, progression and metastasis. Consistent with this, aberrant LPA production, receptor expression and signalling have been reported in various cancer models or patients. It has been suggested that LPA involvement may be important especially in ovarian cancer. LPA concentrations are elevated in the plasma and ascitic £uid of ovarian cancer patients, 7 and ovarian cancer cells constitutively and inducibly produce high concentrations of LPA receptors and demonstrate markedly di¡erent responses to LPA from the normal ovarian surface epithelium. 9 For example, the expression of LPA2 and LPA3 has been reported to be enhanced in malignant ovarian epithelial cells, contributing to the aberrant responses of ovarian cancer cells to LPA. 10 The involvement of LPA is not restricted to ovarian cancer, and several studies have shown that LPA stimulates the initiation and/or progression of cancer of the prostate, breast, melanoma, head and neck, bowel, thyroid and other organs. 7,11--14 Although much has been learned about the physiological roles of LPA through a series of studies on LPA actions and its receptors, the pathways of LPA production had remained unresolved until recently. It is believed that LPA is mainly converted from lysophospholipids in the serum and plasma and that lysophospholipase D (lysoPLD) is the key enzyme for LPA production. Recently, the lysoPLD was puri¢ed from the human plasma and fetal bovine serum, 15, 16 and was found to be identical to the soluble form of autotaxin (ATX), an ecto-nucleotide pyrophosphatase/phosphodiesterase (NPP2) originally isolated as a tumour cell motility-stimulating factor. 17 Due to its lower K m value for lysophosphatidylcholine (LPC) than that for a synthetic substrate of the nucleotide, it was suggested that LPC is a more likely physiological substrate for ATX, and it is now believed that the putative physiological and pathophysiological functions of ATX are accounted for by its ability to produce LPA. 15, 16, 18 In this context, not only LPA, but also lysoPLD/ATX has been shown to contribute to the development, progression and metastasis of several cancers. LysoPLD/ATX mRNA is reportedly overexpressed in various metastatic cancer cells and tissues, such as thyroid, renal cell and breast cancers, and glioblastoma. 19--23 Together with the ¢nding of overexpression of several LPA receptors in several tumour cells, 7, 24, 25 it is speculated that the expression of lysoPLD/ATX and LPA receptors may be closely linked to the invasiveness of cancer cells and cancer cell metastasis.Very recently, a previously unassigned role of ATX in stabilizing vessels through novel LPA signalling pathways has also been revealed by analysis of ATX knockout mice. 26, 27 Prostate cancer seems to be no exception in relation to the involvement of LPA and lysoPLD/ATX in its initiation and progression. LPA has been demonstrated to induce the proliferation of several prostate cancer cell lines 28 and evoke mitogenic responses of prostate cancer cells, 29 and expression of lysoPLD/ATX has also been observed in these cells. 30 In addition, LPA receptors have also been shown to be expressed in prostate cancer cells. 31 These studies clearly suggest the involvement of lysoPLD/ATX and LPA in prostate cancer development. Therefore, in this study, we focused on this involvement of lysoPLD/ATX in the development of prostate cancer; we investigated whether the serum lysoPLD activity may be elevated in patients with prostate cancer as compared with that in healthy controls, and also evaluated the potential usefulness of measurement of serum lysoPLD activity as a diagnostic marker for prostate cancer. However, we unexpectedly found that serum lysoPLD/ATX cannot be a reliable marker of this cancer; on the other hand, our results suggested that it may be a new marker of nutritional status.
Materials and methods

Samples
The serum samples used in this study were residual samples of those obtained for routine laboratory analyses (for clinical purposes) at The University of Tokyo Hospital. Patients diagnosed as having prostate or renal cancer (histologically con¢rmed) at the Department of Urology, The University of Tokyo Hospital, were enrolled for the study. Informed consent was obtained for the usage of the residual samples. The study was approved by The Institutional Research Ethics Committee of the Faculty of Medicine, The University of Tokyo. To obtain the serum samples, whole blood specimens were directly put into glass tubes and left to stand for 15 min at room temperature to allow blood clots to form; then, serum was separated by centrifugation at1500 g for 5 min. We have previously reported observing an increase in the serum lysoPLD activity in patients with chronic liver disease. 32 Therefore, patients with hepatic dysfunction were excluded from this study; such patients were identi¢ed based on the aspartate aminotransferase (AST) (438 IU/L), alanine aminotransferase (ALT) (436 IU/L) and/or the platelet count (o1 Â10 5 /mL).
LysoPLD assay
The serum lysoPLD activity was assessed by measuring choline liberation from the substrate LPC, as previously described. 15 The reactions were performed in 100-mL aliquots; the serum samples (20 mL) were incubated with 2 mmol/L 1-myristoyl (14:0)-LPC (Avanti Polar Lipids Inc., Alabaster, AL, USA) in the presence of 100 mmol/L Tris-HCl, pH 9.0, 500 mmol/L NaCl, 5 mmol/L MgCl 2 , 5 mmol/L CaCl 2 , and 0.05% Triton X-100 for 3 h at 371C. The liberated choline was detected by an enzymatic photometric method using choline oxidase (Asahi Chemical, Tokyo, Japan), horseradish peroxidase (Toyobo, Osaka, Japan), and TOOS reagent (N-ethyl-N-(2-hydoroxy-3-sulphoproryl)-3-methylaniline; Dojindo Molecular Technologies, Inc., Tokyo, Japan) as a hydrogen donor. 33 Absorption of serum lysoPLD activity with immunoprecipitation with anti-ATX monoclonal antibody Serum (1mL) from ¢ve healthy individuals were incubated with the Sepharose 4B (40 mL) conjugated with anti-ATX monoclonal antibody (5E5, rat IgG1) for 2 h at 41C and the resulting supernatant was used for measuring lysoPLD activity, as described above. For control experiments, the same serum was incubated with Sepharose 4B (40 mL) conjugated with control rat IgG1.
Prostate-specific antigen assay
The serum concentrations of PSAwere determined by a two-site immunoenzymetric assay using ST AIA-PACK PA (TOSOH, Co.,Tokyo, Japan) in an automatic analyzer (AIA 21; TOSOH).
Transthyretin assay
The serum transthyretin concentrations were determined by nephelometry using the N Antiserum to Human Prealbumin (Dade Behring Inc., Deer¢eld, IL, USA), in an automatic analyzer (BN II; Dade Behring).
Albumin and haemoglobin measurements
Serum albumin was determined by a colorimetric assay using Clinimate ALB (Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan) in an automatic analyzer (Hitachi 7600; Hitachi Co.,Tokyo, Japan). Haemoglobin was determined by the HemoChrom-Sul¢te Method using LyseS 4 and ISOTON 4 (Beckman Coulter Inc., Fullerton, CA, USA) also in an automatic analyzer (GEN Á St; Beckman Coulter Inc.).
Statistics
The statistical signi¢cance of the di¡erences between the two groups was determined by a paired Student's t test. The correlations were evaluated by linear regression analysis. Po0.05 was considered to be signi¢cant.
Results
We ¢rst checked whether or not the serum lysoPLD activity could be ascribed to ATX. ATX-depleted human serum was prepared from ¢ve healthy individuals with immunoprecipitation with anti-ATX monoclonal antibody, and lysoPLD activity was determined by liberation of choline from LPC. The lysoPLD activity was negligible in the ATX-depleted serum samples (Figure1), indicating that ATX fully accounts for serum lysoPLD activity.
We then determined the serum lysoPLD activity in prostate cancer patients using as reference the serum lysoPLD activity in healthy male control subjects (3.2471.08 nmol/mL/min; mean72 SD; n ¼ 30). The serum enzyme activity in all of the prostate cancer patients (n ¼11) was within the reference range. We also determined the serum PSA concentration in the prostate cancer patients (as is well known, serum PSA is the best marker available yet for prostate cancer 34 ) and analysed its correlation with the serum lysoPLD activity. While the serum PSA concentrations were abnormally high (using the cut-o¡ value of 4 ng/ mL), as expected, in many of the prostate cancer patients, no correlation was detected between the serum lysoPLD activity and the serum PSA (r ¼ 0.324, P40.05) ( Figure 2 ).
Next, we measured the serum lysoPLD activity and PSA in patients who had undergone radical prostatectomy, and examined the in£uence of the surgery on these parameters (Figure 3 ). To exclude the direct in£uence of the surgery, the postoperative blood samples were collected at least eight days after the operation. As control, serum samples were also collected from the same patients before the surgery. It was found that while the serum PSA concentrations markedly decreased as compared with the control concentrations (Po0.001), no signi¢cant change in the serum lysoPLD activity could be detected after the surgery in the prostate cancer patients, con¢rming again that the serum lysoPLD activity was not signi¢cantly increased in prostate cancer patients.
Despite the negative data on the serum lysoPLD activity in the prostate cancer patients, a decrease in the serum lysoPLD activity was observed in the immediate phase after the surgery (radical prostatectomy) in these patients (Figures 4 and 5) . However, the reduction was transient and the concentrations returned to normal within around eight days after the surgery (as shown in Figure 3 ). The time-courses of the changes in the serum lysoPLD activity and other parameters (before and after the operation) in a representative case are shown in Figure 4 . This patient with prostate cancer was followed up for 46 days, and the changes in the serum lysoPLD activity, albumin, transthyretin, and haemoglobin concentrations were monitored. The transient decrease in the serum lysoPLD activity corresponded to the changes in the other nutri-tional status markers. The serum transthyretin appeared to be the most sensitive to the in£uence of surgery; it decreased to about 50% of the preoperative control concentration by the fourth day after the surgery ( Figure 4 ). The serum lysoPLD activity and haemoglobin concentrations declined to about 60% of the control values. Of the four indices, the serum albumin concentration showed the least signi¢cant change (Figure 4 ). We then measured and compared the lysoPLD activity level and those of albumin, transthyretin, and haemoglobin, in samples collected preoperatively and postoperatively (within 7 days of the surgery) in many prostate cancer patients. As predicted from the data shown in Figure 4 , all the four parameters were signi¢cantly decreased after the surgery as compared with the preoperative control values (Po0.001) ( Figure 5 ). Consistent with these data, the serum lysoPLD activity was correlated directly with the albumin (r ¼ 0.356, Po0.001), transthyretin (r ¼ 0.399, Po0.05), and haemoglobin concentrations after the surgery (r ¼ 0.395, Po0.001) ( Figure 6 ).
Finally, we examined whether the decrease in the serum lysoPLD activity after the prostate cancer surgery was speci¢c to patients of prostate cancer. For this purpose, we also conducted the measurements in samples collected from patients with renal cancer. As shown in Figure 7 , the serum lysoPLD activity (Po0.05), albumin (Po0.05) and transthyretin (Po0.001) concentrations in these patients were also signi¢cantly decreased after the surgery (within 7 days) as compared with the preoperative control values; while the haemoglobin concentration also tended to decrease, the di¡erence from the preoperative control value was not statistically signi¢cant (Figure 7 ).
Discussion
The important role of LPA in the development and progression of prostate cancer has been reported by several recent studies. LPA stimulates the inducible nuclear transcription factor-kB (NF-kB) and enhances the survival of prostate cancer cells; 29, 35 it has also been shown to activate PLD activity in human prostate cancer cell lines. 28 Prostate cancer cell lines have been reported to generate18:1 LPA abundantly in the culture medium. 14 Unsaturated LPA (18:1-LPA), but not saturated LPA (16:0-and 18:0-LPA), has been shown to most e¡ectively activate extracellular signal-regulated kinase and phospholipase D. 14 Because LPA3 is the speci¢c receptor for unsaturated LPAs, 36 these results indicate that LPA3 may be involved in the actions of LPA in prostate cancer. It has been shown that lysoPLD preferentially hydrolyses unsaturated LPCs over saturated LPCs. 37 It is also considered that lysoPLD is responsible for the formation of unsaturated LPAs. On the basis of all these reports, we were prompted to investigate whether lysoPLD/ATX might have physiological roles, and also any pathophysiological roles, in prostate cancer.
In this study, we measured the serum lysoPLD/ATX activity in patients with prostate cancer, based on our initial supposition that the serum lysoPLD activity may be a diagnostic marker for prostate cancer. Contrary to our expectation, however, the serum lysoPLD activity in patients with prostate cancer was not statistically di¡erent from that in the controls. Consistent with this ¢nding, there was also no correlation between the serum lysoPLD activity and the serum PSA, the most reliable marker available yet for prostate cancer. Furthermore, there were also no changes in the serum lysoPLD activity after radical prostatectomy, when the samples were collected after at least eight days of surgery to prevent the confounding e¡ects of the surgery on the measurement. We had to admit, therefore, that serum lysoPLD cannot be a marker of prostate cancer. Although measurement of lysoPLD activity in seminal £uid may be important, it was di⁄cult to perform this in the present study using residual serum samples. Probably, prostate cancer cells do not produce su⁄cient lysoPLD to cause a change in the serum lysoPLD activity. Very recently, acylglycerol kinase, which is capable of producing LPA through phosphorylation of monoacylglycerol, was identi¢ed. 38, 39 It is worthy of note that this novel lipid kinase has been reported to be upregulated in prostate cancer as compared with normal prostate tissue from the same patient and that the expression of this kinase in PC-3 prostate cancer cells markedly increased the formation and secretion of LPA. The discrepancy between the importance of LPA in prostate cancers and the lack of upregulation of lysoPLD activity in patients with this cancer may be explained by the actions of this acylglycerol kinase, which plays an important role in the pathophysiology of prostate cancer and formation of LPA.
Although LPA has been implicated in the pathogenesis of various human diseases, including cancer metastasis 40, 41 and cardiovascular diseases, 42 the clinical signi¢cance of the assay of the serum lysoPLD activity remains to be established. There are only a limited number of related reports, as follows. Tokumura et al. 43 demonstrated that the serum lysoPLD activity increased during pregnancy and that the elevated activity induced an increase in the production of bioactive LPA. They also reported an increase in the activity of lysoPLD in patients with threatened preterm delivery. 16 We showed that the serum lysoPLD activity and plasma LPA concentration were increased in patients with chronic liver disease. 32 No data, however, are yet available on the changes in the serum lysoPLD activity in relation to surgery. Based on our present observation, we suggest that the serum lysoPLD could become a new parameter re£ecting insult or damage to the body. The serum lysoPLD activity was found to decrease after operation and seemed to re£ect the severity of postoperative damage or the nutritional status; a good correlation was observed between the serum lysoPLD activity and the conventional nutritional status markers (i.e. serum albumin and transthyretin and haemoglobin) 44 after surgery, in both prostate and renal cancer patients. The nutritional markers such as albumin and transthyretin are negative acute phase proteins.We hence checked the correlation between C-reactive protein and lysoPLD activity; the correlation was not statistically signi¢cant, with the r and P values being --0.126 and 0.308, respectively. Accordingly, we consider that the present observation on the lysoPLD activity changes may not be a re£ection of the in£ammatory response, although the possibility of in£ammation a¡ecting the level of lysoPLD activity cannot be completely excluded. Furthermore, we also checked the correlation between lysoPLD activity and lipid pro¢les; the results were negative. The r and P values for the correlation between the serum lysoPLD activity and total cholesterol concentrations were 0.628 and 0.052, respectively, while those between the serum lysoPLD activity and triglyceride concentrations were 0.268 and 0.521, respectively.
The incidence of malnutrition after operation or in older adults is high; a larger patient population su¡ers from declining nutritional status during hospitalization. Therefore, public and professional recognition of the importance of malnutrition is growing. Several biochemical markers have been employed to detect and monitor protein calorie malnutrition in hospitalized patients. Among these, the serum transthyretin and albumin (synthesized in liver) concentrations are the two most frequently employed markers. In fact, it is well established that these two markers do provide important information predictive of the outcomes in patients with protein calorie malnutrition; patients with low serum transthyretin and albumin concentrations suffered poorer health outcomes and higher costs of care. 45 Albumin acts to both maintain the plasma osmotic pressure and transport substances in the plasma. The serum concentrations of albumin re£ect the net result of hepatic synthesis (12--15 g/day), plasma distribution, and protein loss. Although albumin concentrations are often used as nutritional measures in clinical studies, 46, 47 it is di⁄cult to use it to accurately evaluate the nutritional state over the short term in hospitalized patients and patients with acute diseases, because albumin has a long half-life of approximately 18 days 48 and it takes a longer time for changes in its concentrations to occur to re£ect short-term changes in the nutritional state. On the other hand, transthyretin has a small pool and a short half-life of approximately 48 h, 49 and its measurement provides superior sensitivity for evaluating acute changes in the nutritional state; its concentrations decrease and increase faster than those of albumin (or even transferrin) in cases of protein depletion 50 and nutritional replenishment, respectively. 51, 52 Hence, measurement of serum transthyretin concentrations has been used and recommended for the nutritional assessment of surgical patients. 53--55 Although the pattern of changes in the serum lysoPLD activity in the prostate and renal cancer patients after surgery was similar to those of transthyretin and albumin in the present study, this does not necessarily imply that the in vivo dynamics of lysoPLD is identical to transthyretin or albumin. Rather, recent evidence reveals that the serum lysoPLD activity is also increased in chronic liver disease patients, and that it is well-correlated negatively to the serum albumin concentrations; this is the reason patients with hepatic dysfunction were excluded from this study. This indicates that at least the liver is not the major organ of synthesis of this novel marker.
The mechanism of lysoPLD/ATX production and degradation is not clear yet. LysoPLD/ATX is widely expressed in the body, and the major origin of the serum lysoPLD/ATX is still unknown. Although the synthesis and catabolism of lysoPLD should be clari¢ed to establish the real clinical signi¢cance of lysoPLD/ ATX as a marker of nutritional status, it does o¡er the promise of becoming a new indicator, di¡erent in characteristics from the conventional ones.
